coagulation factor VIII
עודכן לאחרונה 18 Aug 2020
עומד בהנחיות העריכה של Patient
- הורדהורד
- שתף
- Language
- דיון
- Ask Patient
- גרסת שמע
- הוסף למקורות מועדפים בגוגל
ה F8 gene provides instructions for making a protein called coagulation factor VIII. Coagulation factors are a group of related proteins that are essential for the formation of blood clots. After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
בחירות וידאו עבור Genesספריית סרטונים
Normal function
ה F8 gene provides instructions for making a protein called coagulation factor VIII. Coagulation factors are a group of related proteins that are essential for the formation of blood clots. After an injury, clots protect the body by sealing off damaged blood vessels and preventing further blood loss.
Coagulation factor VIII is made chiefly by cells in the liver. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.
Conditions referring to this gene or chromosome
Other names
AHF
antihemophilic factor
coagulation factor VIII, procoagulant component
coagulation factor VIII, procoagulant component (hemophilia A)
DXS1253E
FA8_HUMAN
Factor VIIIF8B
FVIII
HEMA
procoagulant component
Related patient information and medicines

Patient information leaflet
תרומבופיליה
It can lead to venous blood clots, often in unusual sites such as the veins of the gut, liver or... Anticoagulation may be needed and there are other treatments too for this condition. Elevated factor VIII This is pronounced 'factor 8'. It is due to abnormally high levels of factor VIII, which is one of the blood chemicals that promotes clotting..

Patient information leaflet
בדיקות קרישת דם
Blood clotting tests are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. One or more of these tests may be done if a gene... For example, the amount of factor VIII can be measured in a blood sample. (The level is very low or absent in people with haemophilia A.) Platelet.

Patient information leaflet
המופיליה
Haemophilia is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. Haemophilia B is the more common problem and is due to a deficiency of clotting factor IX. המופיליה A is due to a deficiency of clotting factor VIII. By and large,.

Patient information leaflet
רעלת הריון
Complications Most women with pre-eclampsia or HE... The risk of complications increases the more severe the pre-eclampsia becomes. The risk of complications is reduced if pre-eclampsia is diagnosed early and treated. A rare but serious complication מטופל? disseminated intravascular coagulation, which can occur if a woman has had to have many blood.

Patient information leaflet
ושט בארט
The coil then emits heat energy which destroys the abnormal cells. Nearby normal cells then multiply and replace the destroyed abnormal cells. Argon plasma coagulation This treatment uses a jet of argon gas, together with an electric current, to burn away dysplastic cells. Endoscopic mucosal resection (EMR) This is a procedure that is done via.

Patient information leaflet
טחורים
Banding treatment (rubber band ligation) Banding is the most commonly used piles treatment, especially for grade 2 and 3 piles. Infrared coagulation/photocoagulation This method of piles treatment uses infrared light to burn and cut off the circulation to the haemorrhoid, which causes it to shrink in size. It may be as effective as banding.
קריאה נוספת והפניות
- coagulation factor VIII; MedlinePlus, National Library of Medicine.
- Bicocchi MP, Pasino M, Lanza T, Bottini F, Boeri E, Mori PG, Molinari AC, Rosano C, Acquila M. Analysis of 18 novel mutations in the factor VIII gene. Br J Haematol. 2003 Sep;122(5):810-7. doi: 10.1046/j.1365-2141.2003.04494.x.
- Bogdanova N, Markoff A, Eisert R, Wermes C, Pollmann H, Todorova A, Chlystun M, Nowak-Gottl U, Horst J. Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Hum Mutat. 2007 Jan;28(1):54-60. doi: 10.1002/humu.20403.
- Bogdanova N, Markoff A, Pollmann H, Nowak-Gottl U, Eisert R, Wermes C, Todorova A, Eigel A, Dworniczak B, Horst J. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat. 2005 Sep;26(3):249-54. doi: 10.1002/humu.20208.
- Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003 May 24;361(9371):1801-9. doi: 10.1016/S0140-6736(03)13405-8.
- Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol. 2002 Apr;55(2):127-44. doi: 10.1136/mp.55.2.127.
- Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet. 2005 Jun;6(6):488-501. doi: 10.1038/nrg1617.
- Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol. 2006 Feb;83(2):96-102. doi: 10.1532/IJH97.06012.
- Shen BW, Spiegel PC, Chang CH, Huh JW, Lee JS, Kim J, Kim YH, Stoddard BL. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008 Feb 1;111(3):1240-7. doi: 10.1182/blood-2007-08-109918. Epub 2007 Oct 26.
- Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost. 2003 Feb;29(1):11-22. doi: 10.1055/s-2003-37935.
שתפו את מחשבותיכם או חוויותיכם עם אחרים ב קהילות המטופלים שלנו.
הירשמו לניוזלטר של פיישנט
המנה השבועית שלך של עצות בריאות ברורות ואמינות - נכתבה כדי לעזור לך להרגיש מעודכן, בטוח ובשליטה.
על ידי הרשמה אתה מקבל את שלנו מדיניות הפרטיות שלנו. באפשרותך לבטל את המנוי בכל עת. לעולם לא נמכור את הנתונים שלך.

